|
Status |
Public on Aug 20, 2016 |
Title |
WILL2_DMSO_24_2 |
Sample type |
SRA |
|
|
Source name |
Cancer cell line
|
Organism |
Homo sapiens |
Characteristics |
cell line name: WILL2 treatment: DMSO treatment time: 24 h tumor type: dlbcl replicate: 2
|
Treatment protocol |
Cell lines were treated with either AZD5153 or DMSO for 24h
|
Growth protocol |
Cell lines were grown under standard conditions
|
Extracted molecule |
polyA RNA |
Extraction protocol |
RNA isolation was carried out at Expression Analysis (http://www.q2labsolutions.com/) Library construction was carried out at Expression Analysis (http://www.q2labsolutions.com/)
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina HiSeq 2000 |
|
|
Description |
WILL2_DMSO_24_2
|
Data processing |
Reads were soft clipped and provided by the vendor alignment and analysis were performed using bcbio-nextgen v0.7.7 STAR_2.3.1z_r395 was used for alignment htseq v0.6.1 was used to calculate counts FPKM was calculated using Cufflinks v2.1.1 Genome_build: hg19 Supplementary_files_format_and_content: tab-delimited text files include FPKM values for each sample
|
|
|
Submission date |
Aug 19, 2016 |
Last update date |
May 15, 2019 |
Contact name |
Huawei Chen |
E-mail(s) |
Raymond.Chen@astrazeneca.com
|
Organization name |
AstraZeneca
|
Street address |
35 Gatehouse Dr
|
City |
Waltham |
State/province |
MA |
ZIP/Postal code |
02451 |
Country |
USA |
|
|
Platform ID |
GPL11154 |
Series (1) |
GSE85840 |
Transcriptional changes induced by Brd4 inhibitor, AZD5153, in cancer cell lines |
|
Relations |
BioSample |
SAMN05597413 |
SRA |
SRX2035861 |